A Phase I Study of Safety and Tolerability of Acetazolamide With Temozolomide in Adults With Newly Diagnosed MGMT Promoter-Methylated IDH Wildtype Glioblastoma
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
- University of Chicago
- Enrollment
- 10
- Locations
- 2
- Primary Endpoint
- Number of participants with adverse events
Study Overview
Brief Summary
This is a Phase I study that examines the rate of dose limiting side effects in patients with malignant astrocytoma treated with combination acetazolamide (ACZ) and temozolomide (TMZ). Eligible patients must have histologically proven newly diagnosed, O6-methylguanine-DNA methyltransferase (MGMT) methylated WHO grade III or IV astrocytoma and be planning to undergo treatment with standard adjuvant TMZ (after completing treatment with TMZ and ionizing radiation (IR)).
During this study, patients will receive daily oral ACZ with TMZ. During each cycle, ACZ will be started on the day of TMZ initiation and continued for a total of 21 days.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Histologically proven, newly diagnosed IDH wildtype glioblastoma (GBM) that has a methylated MGMT promoter as assessed by the standardized institutional analysis.
- •Patients are eligible if they had a prior low grade astrocytoma and there is subsequent histological evidence of a diagnosis of grade III or IV tumor.
- •Patients must be receiving TMZ as part of their standard adjuvant treatment regimen following treatment with TMZ and Radiation.
- •Patients must have a Karnofsky performance ≥ 60%.
- •Normal organ function as follows:
- •Absolute Neutrophil Count (ANC) ≥ 1.0 x 10^9/ L
- •Platelets ≥ 100 x 10^9 / L
- •Hemoglobin ≥ 8.0 g / dL
- •Age 18 years or older.
- •Kidney function (creatinine level within normal institutional limit, or creatinine clearance ≥ 60 mL/min/1.73 m2 for patients with creatinine level above institutional normal).
- •Liver function (AST/ALT <2.5 X institutional upper limit of normal (ULN), Total bilirubin ≤ 1.5 times ULN, INR within 1.5 times ULN (or if receiving anticoagulant therapy an INR of ≤ 3.0 is allowed with concomitant increase in PT or an aPTT ≤ 2.5 × control).
- •Women able to become pregnant must have a negative pregnancy test within 30 days of registration.
- •Patients must have the ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria
- •Prior invasive malignancy that is not low-grade glioma (except non-melanomatous skin cancer or carcinoma in situ of the cervix) unless the patient has been disease free and off therapy for that disease for a minimum of 3 years.
- •Active systemic infection requiring treatment, including any HIV infection or toxoplasmosis.
- •Other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation or study drug administration.
- •Systemic corticosteroid therapy, >8 mg of dexamethasone daily (or equivalent) at study enrollment.
- •Pregnant women are excluded from this study, where pregnancy is confirmed by a positive serum beta-hCG laboratory test. Breast-feeding should be discontinued.
- •Hypersensitivity to acetazolamide or sulfonamides.
Arms & Interventions
Acetazolamide with Temozolomide
Subjects will receive daily ACZ together with TMZ in 28 day cycles for up to 6 cycles if they do not experience either disease worsening or unacceptable side effects.
Intervention: Acetazolamide (Drug)
Acetazolamide with Temozolomide
Subjects will receive daily ACZ together with TMZ in 28 day cycles for up to 6 cycles if they do not experience either disease worsening or unacceptable side effects.
Intervention: Temozolomide (Drug)
Outcomes
Primary Outcomes
Number of participants with adverse events
Time Frame: 28 Days
To determine the safety, tolerability and adverse event profile of adding acetazolamide to temozolomide in patients with newly diagnosed malignant astrocytoma.
Secondary Outcomes
- Time until overall survival (OS)(From start date of therapy to the date of death from any cause, whichever may come first, assessed up to 100 months)
- To determine feasibility of cooperative interaction between multiple sites(End of study enrollment period (approximately 6 years))
- Measure objective response rate (ORR); change in tumor size(6 months)
- Analysis of formalin fixed paraffin embedded surgical specimens.(Through study completion an average of one year)
- Time until progression free survival (PFS)(6 months)